IO BIOTECH INC (IOBT)
US4497781090 - Common Stock
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:...
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank
Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in...
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights...
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech Announces Participation in Upcoming Investor Conferences...
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated...
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf,...
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head...
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial...
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech Announces Participation in Upcoming Investor Conferences...
IOBT Stock Earnings: IO Biotech Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips IO Biotech (NASDAQ:IOBT) just reported results for the second quarter of 2024.I...
IOBT Stock Earnings: IO Biotech Beats EPS for Q2 2024
IOBT stock results show that IO Biotech beat analyst estimates for earnings per share the second quarter of 2024.
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights...
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise.
IO Biotech to Present at Jefferies Global Healthcare Conference
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
IOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024
IOBT stock results show that IO Biotech beat analyst estimates for earnings per share the first quarter of 2024.
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead...
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103...
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer...
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting ...
IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023
IOBT stock results show that IO Biotech missed analyst estimates for earnings per share the fourth quarter of 2023.
IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips IO Biotech (NASDAQ:IOBT) just reported results for the fourth quarter of 2023.I...
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results...
IO Biotech to Present at 44th Annual Cowen Health Care Conference
IO Biotech to Present at 44th Annual Cowen Health Care Conference ...
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial ...
IO Biotech executive discloses purchase of 10K shares (NASDAQ:IOBT)
Learn about the recent insider trading activity at IO Biotech, including a Chief Accounting Officer's purchase of 10,000 shares.